Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

Rh Blood Group

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Seventh Åland Island Meeting on von Willebrand Disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Same author

Von Willebrand disease.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026

Same author

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026

Same author

The landmark contribution by Erik von Willebrand.

Haematologica·2026

Same author

Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural study.

Research and practice in thrombosis and haemostasis·2025

Same author

Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype.

HemaSphere·2025

Search research articles

Related Experiment Video

Updated: May 17, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

Von Willebrand disease.

Erik Berntorp¹

¹Malmö Centre for Thrombosis and Haemostasis, Lund University, Malmö, Sweden. erik.berntorp@med.lu.se

Pediatric Blood & Cancer

|October 31, 2012

Summary

Long-term prophylaxis is being evaluated for severe Von Willebrand disease (VWD). The Von Willebrand disease prophylaxis network (VWD PN) aims to establish evidence-based treatment guidelines for VWD patients unresponsive to other therapies.

Area of Science:

Hematology
Bleeding Disorders
Clinical Research

Background:

Long-term prophylaxis is established in hemophilia but less understood in Von Willebrand disease (VWD).
Existing cohort studies on VWD prophylaxis are limited.
Severe VWD, particularly type 3, often presents challenges with current treatment options.

Purpose of the Study:

To investigate the efficacy and optimal dosing of long-term prophylaxis in clinically severe Von Willebrand disease.
To establish an international network (VWD PN) for collaborative research on VWD prophylaxis.
To provide robust evidence for guiding prophylaxis decisions in VWD patients unresponsive to standard treatments.

Main Methods:

Formation of the Von Willebrand disease prophylaxis network (VWD PN) for international collaboration.

More Related Videos

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Related Experiment Videos

Last Updated: May 17, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Conducting cohort studies to evaluate prophylaxis in severe VWD.

Focusing on patients with type 3 VWD or those refractory to other treatments.

Main Results:

Ongoing studies by the VWD PN are gathering data on prophylaxis outcomes.
Preliminary findings aim to identify patient subgroups who benefit most from prophylaxis.
Dosing regimens are being evaluated for safety and efficacy.

Conclusions:

The VWD PN is generating crucial evidence for VWD prophylaxis.
Findings are expected to inform clinical practice and improve treatment for severe VWD.
Further research will refine prophylaxis strategies and dosing for Von Willebrand disease.